Velpatasvir

• Background:

  Velpatasvir is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor.1 It is a component of Epclusa® and Vosevi®, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV. It displayed EC50’s for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-CoV-2 spike protein and may be a potential therapeutic.2

• Conjugation:

  Unconjugated

• Buffer:

  Pale yellow solid

• Storage Conditions:

  -20°C